Bayer's Xarelto Gets European Approval For Blood Clots In Lungs

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said its oral anti blood coagulant Xarelto got the European Commission's approval for the treatment of Pulmonary Embolism or PE and the Prevention of Recurrent Deep Vein Thrombosis or DVT.

Pulmonary Embolism is caused by the detached blood clots that causes block in deep veins or in the lungs that kill more than 2,300 people every day worldwide. PE is a leading cause in hospital death and requires urgent action to save lives.

Xarelto is a single-drug solution and protects for as long as required. It was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC.

The European Commission approval in adults is based on the clinical findings from the pivotal, global Phase III EINSTEIN-PE study, with 4,833 patients enrolled, EINSTEIN-PE is the largest study ever conducted in the acute treatment of PE.

For comments and feedback contact: editorial@rttnews.com

Follow RTT